机译:Ixazomib在高风险复发/难治性骨髓瘤患者中显着延长了无进展的生存期
Univ Canc Ctr Toulouse Inst Natl Sante Lab Genom Myeloma Toulouse France;
Univ Calgary Southern Alberta Canc Res Inst Calgary AB Canada;
Natl Univ Canc Inst Dept Hematol Oncol Singapore Singapore;
St Istvan St Laszlo Hosp Budapest Hungary;
IPOPFG EPE Oporto Portugal;
Univ Hosp Brno Dept Internal Med Hematol &
Oncol Brno Czech Republic;
Christchurch Hosp Dept Haematol Christchurch New Zealand;
Univ Torino AOU S Giovanni Battista Div Hematol Turin Italy;
Univ Bologna Seragnoli Inst Hematol Bologna Italy;
Univ Hosp Ulm Dept Internal Med 3 Ulm Germany;
Oncol Specialist Hosp Dept Hematol Oncol Brzozow Poland;
Chaim Sheba Med Ctr Hematol Div Tel Hashomer Israel;
Mayo Clin Rochester MN USA;
Hadassah Med Ctr Jerusalem Israel;
Mayo Clin Rochester MN USA;
Clin Univ Navarra Inst Invest Sanitaria Navarra IDISNA CIMA Ctr Invest Biomed Red Canc CIBERONC;
Millennium Pharmaceut Inc Cambridge MA USA;
Millennium Pharmaceut Inc Cambridge MA USA;
Millennium Pharmaceut Inc Cambridge MA USA;
Millennium Pharmaceut Inc Cambridge MA USA;
Millennium Pharmaceut Inc Cambridge MA USA;
Univ Hosp Hematol Dept Hotel Dieu Nantes France;
Dana Farber Canc Inst Boston MA 02115 USA;
机译:Ixazomib在高风险复发/难治性骨髓瘤患者中显着延长了无进展的生存期
机译:较高的c-MYC表达与依沙米单抗-来那度胺-地塞米松(IRd)无进展生存期(PFS)相对于安慰剂-Rd的关联:电气石-MM1期3期研究在复发/难治性多发性骨髓瘤(RRMM)中的生物标志物分析
机译:具有口服蛋白酶体抑制剂(PI)的维持治疗Ixazomib在新诊断的多发性骨髓瘤(NDMM)患者中的自体干细胞移植(ASCT)之后显着延长了无进展的存活率(PFS):第3期Tourmaline-MM3试验
机译:接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:在常规临床实践中复发和难治多骨髓瘤(RD)对Lenalalomide和地塞米松(IRD)的肝氮杂胺和地塞米松(IRD)的生存益处
机译:在常规临床实践中复发和难治多骨髓瘤(RD)对Lenalalomide和地塞米松(IRD)的肝氮杂胺和地塞米松(IRD)的生存益处